The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities

Ähnliche Einträge

• Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture
  von: Archer, Richard H., et al.
  Veröffentlicht: (2000)
• Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
  von: Demeter, L. M., et al.
  Veröffentlicht: (2000)
• ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy
  von: Para, Michael F., et al.
  Veröffentlicht: (1999)
• Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase.
  von: DeStefano, J J, et al.
  Veröffentlicht: (1993)
• Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H
  von: Marchand, Christophe, et al.
  Veröffentlicht: (2008)